Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Abstract

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

What is claimed is:  
     
         1 . A compound of Formula I, including pharmaceutically acceptable salts thereof,  
       
         
           
           
               
               
           
         
       
       wherein: 
 Q is selected from the group consisting of:  
                     
 R 1 , R 2 , R 3 , and R 4 , are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, COR 56 , XR 57  C(O)R 7 , C(O)NR 55 R 56 , B, D, and E with the proviso that at least one of R 1 -R 4  is selected from B or E;  
 wherein—represents a carbon-carbon bond or does not exist;  
 m is 1 or 2;  
 R 5  is hydrogen or (CH 2 ) n CH 3 , —C(O)(CH 2 ) n CH 3 , —C(O)O(CH 2 ) n CH 3 , —C(O) (CH 2 ) n N(CH 3 ) 2  wherein n is 0-5;  
 R 6 is O or does not exist;  
 A is selected from the group consisting of C 1-6 alkoxy, aryl and heteroaryl; in which said aryl is phenyl or napthyl; said heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, benzoimidazolyl and benzothiazolyl; and said aryl or heteroaryl is optionally substituted with one or two of the same or different members selected from the group consisting of amino, nitro, cyano, hydroxy, C 1-6 alkoxy, —C(O)NH 2 , C 1-6 alkyl, —NHC(O)CH 3 , halogen and trifluoromethyl;  
                     
 B is selected from the group consisting of —C(=NR 46 )(R 47 ), C(O)NR 40 R 41 , aryl, heteroaryl, heteroalicyclic, S(O) 2 R 8 , C(O)R 7 , XR 8a , (C 1-6 )alkylNR 40 R 41 , (C 1-6 )alkylCOOR 8b ; wherein said aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from the group F; wherein aryl is napthyl or substituted phenyl; wherein heteroaryl is a mono or bicyclic system which contains from 3 to 7 ring atoms for a mono cyclic system and up to 12 atoms in a fused bicyclic system, including from 1 to 4 heteroatoms; wherein heteroalicyclic is a 3 to 7 membered mono cyclic ring which may contain from 1 to 2 heteroatoms in the ring skeleton and which may be fused to a benzene or pyridine ring;  
 q is 0, 1, or 2;  
 D is selected from the group consisting of (C 1-6 )alkyl and (C 2-6 )alkenyl; wherein said (C 1-6 )alkyl and (C 2-6 )alkenyl are optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from the group consisting of C(O)NR 55 R 56 , hydroxy, cyano and XR 57 ;  
 E is selected from the group consisting of (C 1-6 )alkyl and (C 2-6 )alkenyl; wherein said (C 1-6 )alkyl and (C 2-6 )alkenyl are independently optionally substituted with a member selected from the group consisting of phenyl, heteroaryl, SMe, SPh, —C(O)NR 56 R 57 , C(O)R 57 , SO 2 (C 1-6 )alkyl and S0 2 Ph; wherein heteroaryl is a monocyclic system which contains from 3 to 7 ring atoms, including from 1 to 4 heteroatoms;  
 F is selected from the group consisting of (C 1-6 )alkyl, (C 3-7 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, (C 1-6 )alkoxy, aryloxy, (C 1-6 )thioalkoxy, cyano, halogen, nitro, —C(O)R 57 , benzyl, —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 C(O)—(C 3-6 )cycloalkyl, —NR 42 C(O)-aryl, —NR 42 C(O)-heteroaryl, —NR 42 C(O)-heteroalicyclic, a 4, 5, or 6 membered ring cyclic N-lactam, —NR 42 S(O) 2 —(C 1-6 )alkyl, —NR 42 S(O) 2 —(C 3-6 cycloallkyl, —NR 42 S(O)2-aryl, —NR 42 S(O) 2 -heteroaryl, —NR 42 S(O)2-heteroalicyclic, S(O) 2 (C 1-6 )alkyl, S(O) 2 aryl, —S(O)2 NR 42 R 43 , NR 42 R 43 , (C 1-6 )alkylC(O)NR 42 R 43 , C(O)NR 42 R 43 , NHC(O)NR 42 R 43 , OC(O)NR 42 R 43 , NHC(O)OR 54 , (C 1-6 )alkylNR 42 R 43 , COOR 54  and (C 1-6 )alkylCOOR 54 ; wherein said (C 1-6 )alkyl, (C 3-7 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, (C 1-6 )alkoxy, and aryloxy, are optionally substituted with one to nine same or different halogens or from one to five same or different substituents selected from the group G; wherein aryl is phenyl; heteroaryl is a monocyclic system which contains from 3 to 7 ring atoms, including from 1 to 4 heteroatoms; heteroalicyclic is selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, piperidine, tetrahydrofuran, tetrahydropyran, azepine, and morpholine;  
 G is selected from the group consisting of (C 1-6 )alkyl, (C 3-7 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, (C 1-6 )alkoxy, aryloxy, cyano, halogen, nitro, —C(O)R 57 , benzyl, —NR 48 C(O)—(C 1-6 )alkyl, —NR 48 C(O)—(C 3-6 )cycloalkyl, —NR 48 C(O)-aryl, —NR 48 C(O)-heteroaryl, —NR 48 C(O)-heteroalicyclic, a 4, 5, or 6 membered ring cyclic N-lactam, —NR 48 S(O) 2 —(C 1-6 )alkyl, —NR 48 S(O) 2 —(C 3-6 )cycloalkyl, —NR 48 S(O)2-aryl, —NR 48 S(O) 2 -heteroaryl, —NR 48 S(O)2-heteroalicyclic, sulfinyl, sulfonyl, sulfonamide, NR 48 R 49 , (C 1-6 )alkyl C(O)NR 48 R 49 , C(O)NR 48 R 49 , NHC(O)NR 48 R 49 , OC(O)NR 48 R 49 , NHC(O)OR 54 , (C 1-6 )alkylNR 48 R 49 , COOR 54 , and (C 1-6 )alkylCOOR 54 ; wherein aryl is phenyl; heteroaryl is a monocyclic system which contains from 3 to 7 ring atoms, including from 1 to 4 heteroatoms; heteroalicyclic is selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, piperidine, tetrahydrofuran, tetrahydropyran, azepine, and morpholine;  
 R 7  is selected from the group consisting of aryl, heteroaryl, and heteroalicyclic; wherein said aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to three same or different halogens or with from one to three same or different substituents selected from the group F;  
 wherein for R 7 , R 8 , R 8a , R 8b  aryl is phenyl; heteroaryl is a mono or bicyclic system which contains from 3 to 7 ring atoms for mono cyclic systems and up to 10 atoms in a bicyclic system, including from 1 to 4 heteroatoms; wherein heteroalicyclic is selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, piperidine, tetrahydrofuran, tetrahydropyran, azepine, and morpholine;  
 R 8  is selected from the group consisting of hydrogen, (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkenyl, (C 2-6 )alkynyl, aryl, heteroaryl, and heteroalicyclic; wherein said (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkenyl, (C 2-6 )alkynyl, aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to six same or different halogens or from one to five same or different substituents selected from the group F;  
 R 8a  is a member selected from the group consisting of aryl, heteroaryl, and heteroalicyclic; wherein each member is independently optionally substituted with one to six same or different halogens or from one to five same or different substituents selected from the group F;  
 R 8b  is selected from the group consisting of hydrogen, (C 1-6 )alkyl and phenyl;  
 R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl; wherein said (C 1-6 )alkyl is optionally substituted with one to three same or different halogens;  
 X is selected from the group consisting of NH or NCH 3 , O, and S;  
 R 40  and R 41  are independently selected from the group consisting of (a) hydrogen; (b) (C 1-6 )alkyl or (C 3-7 )cycloalkyl substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F; and (c) (C 1-6 )alkoxy, aryl, heteroaryl or heteroalicyclic; or R 40  and R 41  taken together with the nitrogen to which they are attached form a member selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, 4-NMe piperazine, piperidine, azepine, and morpholine; and wherein said aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F; wherein for R 40  and R 41  aryl is phenyl; heteroaryl is a monocyclic system which contains from 3 to 6 ring atoms, including from 1 to 4 heteroatoms; heteroalicyclic is selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, piperidine, tetrahydrofuran, tetrahydropyran, azepine, and morpholine; provided when B is C(O)NR 40 R 41 , at least one of R 40  and R 41  is not selected from groups (a) or (b);  
 R 42  and R 43  are independently selected from the group consisting of hydrogen, (C 1-6 )alkyl, allyl, (C 1-6 )alkoxy, (C 3-7 )cycloalkyl, aryl, heteroaryl and heteroalicyclic; or R 42  and R 43  taken together with the nitrogen to which they are attached form a member selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, 4-NMe piperazine, piperidine, azepine, and morpholine; and wherein said (C 1-6 )alkyl, (C 1-6 )alkoxy, (C 3-7 )cycloalkyl, aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group G; wherein for R 42  and R 43  aryl is phenyl; heteroaryl is a monocyclic system which contains from 3 to 6 ring atoms, including from 1 to 4 heteroatoms; heteroalicyclic is a member selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, piperidine, tetrahydrofuran, tetrahydropyran, azepine, and morpholine;  
 R a  and R b  are each independently H, (C 1-6 )alkyl or phenyl;  
 R 46  is selected from the group consisting of H, OR 57 , and NR 55 R 56 ;  
 R 47  is selected from the group consisting of H, amino, halogen, phenyl, and (C 1-6 )alkyl;  
 R 48  and R 49  are independently selected from the group consisting of hydrogen, (C 1-6 )alkyl and phenyl;  
 R 50  is selected from the group consisting of H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, and benzyl; wherein each of said (C 1-6 )alkyl, (C 3-7 )cycloalkyl and benzyl are optionally substituted with one to three same or different halogen, amino, OH, CN or NO 2 ;  
 R 54  is selected from the group consisting of hydrogen and (C 1-6 )alkyl;  
 R 54  is (C 1-6 )alkyl;  
 R 55  and R 56  are independently selected from the group consisting of hydrogen and (C 1-6 )alkyl; and  
 R 57  is selected from the group consisting of hydrogen, (C 1-6 )alkyl and phenyl.  
 
     
     
         2 . A compound of  claim 1 , including pharmaceutically acceptable salts thereof wherein: 
 R 1  is hydrogen;    Q is either:                          wherein R 2  is selected from the group consisting of hydrogen, halogen, hydroxy, —O(C 1-6 )alkyl, cyano, nitro and XR 57 ;    wherein R 3  is selected from the group consisting of hydrogen, halogen, hydroxy, —O(C 1-6 )alkyl, cyano, —COOR 56 , nitro, XR 57 ; phenyl optionally substituted with one to three same or different halogens or one of methoxy, hydroxy or XR 57 ; furyl, oxazolyl, or pyrazolyl, independently optionally substituted with halogen, methoxy, (C 1-3 )alkyl or XR 57 ; or    (b) Q is:                          wherein R 2  and R 3  are independently selected from the group consisting of hydrogen, halogen, hydroxy, —O(C 1-6 )alkyl, cyano, nitro, —COOR 56 , XR 57 , —C(O) NR 55 R 56 ; phenyl optionally substituted with one to three same or different halogens or one of methoxy, hydroxy or XR 57 ; furyl, oxalzolyl or pyrazolyl, independently optionally substituted with (C 1-3 )alkyl, halogen, methoxy or XR 57 ;    and for both (a) and (b):    m is 2;    R 5  is hydrogen;    R 6  does not exist;    A is selected from the group consisting of C 1-6 alkoxy, aryl and heteroaryl; wherein said aryl is phenyl; heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl and isoxazolyl; and said aryl or heteroaryl is optionally substituted with one or two of the same or different members selected from the group consisting of amino, cyano, hydroxy C 1-6 alkoxy, C 1-6 alkyl, —NHC(O)CH 3 , halogen and trifluoromethyl;    represents a carbon-carbon bond;    X is NH or NCH 3 ;    R 57  is H or (C 1-3 )alkyl; and    R 55  and R 56  are independently H or (C 1-6 )alkyl.    
     
     
         3 . A compound of  claim 2 , including pharmaceutically acceptable salts thereof, wherein: 
 A is selected from the group consisting of phenyl and heteroaryl; wherein heteroaryl is pyridinyl, furanyl or thienyl; and said phenyl or said heteroaryl is optionally substituted with one to two of the same or different amino, C 1-6 alkyl, hydroxy, or halogen;    R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are each independently hydrogen or methyl with the proviso that only one is methyl;    Q is either:                          and then R 2  is selected from the group consisting of hydrogen, halogen and methoxy; and    R 3  is hydrogen; or    (b) Q is:                          and R 2  is halogen or hydrogen and R 3  is hydrogen;    and for both (a) and (b):    R 4  is selected from the group consisting of B;    B is selected from the group consisting of —C(O)NR 40 R 41 , substituted phenyl, heteroaryl, oxazoline, pyrazinone and methylene dioxy or ethylene dioxy fused to a benzene or pyridine; wherein said heteroaryl or phenyl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.    
     
     
         4 . A compound of  claim 3 , including pharmaceutically acceptable salts thereof, wherein: 
 B is selected from the group consisting of —C(O)NR 40 R 41 , substituted phenyl and heteroaryl; wherein said phenyl is substituted and heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F;    F is selected from the group consisting of (C 1-6 )alkyl, (C 3-6 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, (C 1-6 )alkoxy, (C 1-6 )thioalkoxy, cyano, halogen, —C(O)R 57 , benzyl, —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 C(O)—(C 3-6 )cycloalkyl, —NR 42 C(O)-aryl, —NR 42 C(O)-heteroaryl, —NR 42 C(O)-heteroalicyclic, 4, 5, or 6 membered ring cyclic N-lactam, —NR S(O) 2 —(C 1-6 )alkyl, —NR 42 R 43 , C(O)NR 42 R 43  and COOR 54 ; wherein said (C 1-6 )alkyl, (C 3-6 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, (C 1-6 )alkoxy, are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group G;    G is selected from the group consisting of (C 1-6 )alkyl, hydroxy, (C 1-6 )alkoxy, halogen, —NR 48 C(O)—(C 1-6 )alkyl, —NR 48 C(O)—(C 3 )cycloalkyl, 4, 5, or 6 membered ring cyclic N-lactam, —NR 48 S(O) 2 —(C 1-6 )alkyl, NR 48 R 49 , (C 1-6 )alkyl C(O)NR 48 R 49 , C(O)NR 48 R 49  and (C 1-6 )alkylNR 48 R 49 ;    R 40  is hydrogen; and    R 41  is selected from the group consisting of (C 1-6 )alkyl, (C 3-7 )cycloalkyl, phenyl and heteroaryl; wherein said (C 1-6 )alkyl, (C 3-7 )cycloalkyl, phenyl, or heteroaryl are substituted with one to three same or different halogens or one to two same or different substituents selected from the group consisting of methyl, (C 1-3 )alkoxy, heteroaryl and aryl; wherein said aryl or heteroaryl are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group consisting of (C 1-6 )alkyl, hydroxy, (C 1-6 )alkoxy, —NR 42 C(O)—(C 1-6 )alkyl, NR 42 R 43  and C(O)NR 42 R 43 .    
     
     
         5 . A compound of  claim 4 , including pharmaceutically acceptable salts thereof, wherein: 
 Q is                          A is Phenyl, 2-pyridyl, or 3-pyridyl;    B is selected from the group consisting of —C(O)NR 40 R 41  or heteroaryl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.    
     
     
         6 . A compound of  claim 5 , including pharmaceutically acceptable salts thereof, wherein: 
 B is heteroaryl, wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.    
     
     
         7 . A compound of  claim 4 , including pharmaceutically acceptable salts thereof, wherein: 
 Q is                          R 2  is selected from the group consisting of hydrogen, halogen, and methoxy;    R 4  is B;    B is selected from the group consisting of —C(O)NR 40 R 41  or heteroaryl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F;    
     
     
         8 . A compound of  claim 7 , including pharmaceutically acceptable salts thereof, wherein: 
 A is phenyl, 2-pyridyl, or 3-pyridyl.    
     
     
         9 . A compound of  claim 8  including pharmaceutically acceptable salts thereof, wherein: 
 B is —C(O)NR 40 OR 41 .  
 
     
     
         10 . A compound of  claim 8  including pharmaceutically acceptable salts thereof, wherein: 
 B is heteroaryl, wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.  
 
     
     
         11 . A compound of  claim 4  wherein: 
 F is selected from the group consisting of (C 1-6 )alkyl, (C 3-6 )cycloalkyl (C 1-6 )alkoxy, hydroxy, heteroaryl, heteroalicyclic, methoxy, —S(C 1-3 )alkyl, halogen, —C(O)R 57 , C(O)NR 42 R 43 , —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 C(O)—(C 3-6 )cycloalkyl, —NR 42 C(O)-aryl, —NR 42 C(O)-heteroaryl, —NR 42 C(O)-heteroalicyclic, 4, 5, or 6 membered ring cyclic N-lactam, —NR 42 S(O) 2 —(C 1-6 )alkyl, —NR 42 S(O) 2 —(C 3-6 )cycloalkyl, —NR 42 S(O)2-aryl, —NR 42 S(O) 2 -heteroaryl, —NR 42 S(O)2-heteroalicyclic, NR 42 R 43 , NR 55 (C 1-3 )alkylNR 55 R 56  and COOR 54 .  
 
     
     
         12 . A compound of  claim 11  wherein: 
 A is phenyl, 2-pyridyl, or 3-pyridyl.  
 
     
     
         13 . A compound of  claim 4 , including pharmaceutically acceptable salts thereof, wherein: 
 Q is                          R 2  is selected from the group consisting of hydrogen and methoxy;    R 3  is hydrogen; and    B is selected from the group consisting of —C(O)NR 40 R 41  and heteroaryl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.    
     
     
         14 . A compound of  claim 8  wherein R 2  is fluoro.  
     
     
         15 . A compound of  claim 8  wherein R 2  is methoxy.  
     
     
         16 . A compound of  claim 8  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole, pyridyl, indole, azaindole, and diaza-indole; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.  
 
     
     
         17 . A compound of  claim 5  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole, pyridyl, indole, azaindole, and diaza-indole; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.  
 
     
     
         18 . A compound of  claim 13  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole, pyridyl, indole, azaindole, and diaza-indole; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.  
 
     
     
         19 . A compound of  claim 7  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole, pyridyl, indole, azaindole, and diaza-indole; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.  
 
     
     
         20 . A compound of  claim 6  wherein: 
 B is heteroaryl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , -thiazole, pyrrole, piperazine, pyrrolidine and N-pyrrolidone.  
 
     
     
         21 . A compound of  claim 7  wherein: 
 B is —C(O)NH-heteroaryl wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6  alkyl), -methoxy, —NHC(C 1 -C 6  alkyl) and —N(C 1 -C 6  alkyl) 2 .  
 
     
     
         22 . A compound of  claim 10  wherein: 
 B is heteroaryl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6 alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NHC(C 1 -C 6  alkyl), —N(C 1 -C 6  alkyl) 2 , -heteroaryl and a 4, 5, or 6 membered cyclic N-lactam.  
 
     
     
         23 . A compound of  claim 9  wherein: 
 B is —C(O)NH-heteroaryl wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6  alkyl), -methoxy, —NHC(C 1 -C 6  alkyl) and —N(C 1 -C 6  alkyl) 2 .  
 
     
     
         24 . A compound of  claim 16  wherein: 
 B is heteroaryl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6 alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , -thiazole, pyrrole, piperazine, pyrrolidine and N-pyrrolidone.  
 
     
     
         25 . A compound of  claim 13  wherein: 
 B is —C(O)NH-heteroaryl wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6  alkyl), -methoxy, —NHC(C 1 -C 6  alkyl) and —N(C 1 -C 6  alkyl) 2 .  
 
     
     
         26 . A compound of  claim 5  wherein: 
 B is thienyl.  
 
     
     
         27 . A compound of  claim 24  wherein: 
 B is thienyl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , heteroaryl, piperazine, pyrrolidine, N-pyrrolidone and trifluoromethyl.  
 
     
     
         28 . A compound of  claim 10  wherein: 
 B is thienyl.  
 
     
     
         29 . A compound of  claim 27  wherein: 
 B is thienyl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of hydroxy, C 1 -C 6  alkyl, amino, —NHC(O)—(C 1 -C 6  alkyl), —C(O)—NH 2 , C(O)NHMe, C(O)NMe 2  and —NR 55 R 56 .  
 
     
     
         30 . A compound of  claim 10  wherein: 
 B is thienyl optionally substituted with one to three same or different halogens or a substituent selected from the group consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , heteroaryl, piperazine, pyrrolidine, N-pyrrolidone and trifluoromethyl.  
 
     
     
         31 . A compound of  claim 16  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole and pyridyl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group F consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , heteroaryl, piperazine, pyrrolidine, N-pyrrolidone and trifluoromethyl.  
 
     
     
         32 . A compound of  claim 17  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole and pyridyl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group F consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , heteroaryl, piperazine, pyrrolidine, N-pyrrolidone and trifluoromethyl.  
 
     
     
         33 . A compound of  claim 18  wherein: 
 B is heteroaryl selected from the group consisting of thiazole, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, furyl, thienyl, oxazole, oxadiazole, thiadiazole, pyrimidine, pyrazole, triazine, triazole, tetrazole and pyridyl; wherein said heteroaryl is optionally substituted with one to three same or different halogens or a substituent selected from the group F consisting of hydroxy, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 3  thioalkoxy, amino, —C(O)H, —COOH, —COOC 1 -C 6  alkyl, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NR 55 R 56 , NR 55 R 56 —(C 1 -C 6  alkyl)-NR 55 R 56 , heteroaryl, piperazine, pyrrolidine, N-pyrrolidone and trifluoromethyl.  
 
     
     
         34 . A compound of  claim 3  which is depicted in Table 2.  
     
     
         35 . A compound of  claim 3  which is depicted in Table 2-1.  
     
     
         36 . A compound of  claim 3  which is depicted in Table 3.  
     
     
         37 . A compound of  claim 3  which is depicted in Table 4.  
     
     
         38 . A compound of  claim 3  which is depicted in Table 5.  
     
     
         39 . A compound of  claim 1  wherein: 
 A is selected from the group consisting of phenyl and heteroaryl; wherein heteroaryl is pyridinyl, furanyl or thienyl; wherein said phenyl or heteroaryl is independently optionally substituted with one to two of the same or different amino, C 1-6 alkyl, or halogen;  
 represents a carbon-carbon bond;  
 R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are each independently hydrogen or methyl, with the proviso that only zero, one, or two is methyl;  
 Q is either:  
                     
 R 2  is selected from the group consisting of hydrogen, halogen, and methoxy; and  
 R 3  is hydrogen; or  
 (b) Q is:  
                     
 R 2  and R 3  are hydrogen;  
 and for both (a) and (b):  
 R 4  is selected from the group consisting of B;  
 B is heteroaryl selected from the group consisting of triazole, pyrazole, oxazole, pyrazine, pyrimidine and oxadiazole; wherein said heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F;  
 F is selected from the group consisting of (C 1-6 )alkyl, heteroaryl, —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 R 43  and C(O)NR 42 R 43 ;  
 R 5  is hydrogen;  
 R 6  does not exist; and  
 R 42  and R 43  are independently selected from the group consisting of hydrogen and (C 1-6 )alkyl; or R 42  and R 43  taken together with the nitrogen to which they are attached form a heteroalicyclic selected from the group consisting of aziridine, azetidine, pyrrolidine, piperazine, tetrahydrofuran, tetrahydropyran, azepine and morpholine.  
 
     
     
         40 . A compound of  claim 39  wherein: 
 R 2  is H, Cl, F, or methoxy; and  
 R 4  is selected from the group consisting of  
                     
 
     
     
         41 . A compound of  claim 40  wherein: 
 R 2  is methoxy or fluoro; and  
 one of R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , or R 16  is methyl and the others are hydrogen.  
 
     
     
         42 . A compound of  claim 40  wherein: 
 R 2  is methoxy; and  
 R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are each hydrogen.  
 
     
     
         43 . A compound of  claim 41  wherein: 
 one of R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , or R 16  is (R)-methyl and the others are hydrogen.  
 
     
     
         44 . A compound of  claim 41  wherein: 
 one of R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , or R 16  is (S)-methyl and the others are hydrogen.  
 
     
     
         45 . A compound of  claim 39  wherein: 
 R 2  is methoxy, hydrogen, chloro, or fluoro; and  
 R 4  is oxadiazole.  
 
     
     
         46 . A compound of  claim 54  wherein: 
 R 2  is methoxy, hydrogen, chloro or fluoro; and  
 R 4  is oxadiazole substituted with a single fluoro, chloro, amino or methyl group.  
 
     
     
         47 . A compound of  claim 2 , including pharmaceutically acceptable salts thereof, wherein: 
 A is selected from the group consisting of phenyl and heteroaryl; wherein said heteroaryl is pyridinyl, furanyl or thienyl; and said phenyl or said heteroaryl is optionally substituted with one to two of the same or different amino, C 1-6 alkyl, hydroxy, or halogen;    R 9 , R 10 , R 11 , R 12 , R 15 , and R 16  are each hydrogen;    R 13  and R 14  are each independently hydrogen or methyl with the proviso that only one is methyl;    Q is either:                          R 2  is selected from the group consisting of hydrogen, halogen and methoxy; and    R 3  is hydrogen; or    (b) Q is:                          and R 2  is halogen or hydrogen and R 3  is hydrogen;    and for both (a) and (b):    R 4  is selected from the group consisting of B; and    B is selected from the group consisting of —C(O)NR 40 R 41 , substituted phenyl, heteroaryl, oxazoline, pyrazinone, methylene dioxy or ethylene dioxy fused to a benzene or pyridine; wherein said heteroaryl or phenyl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F.    
     
     
         48 . A compound of  claim 47 , including pharmaceutically acceptable salts thereof, wherein: 
 B is selected from the group consisting of —C(O)NR 40 R 41 , substituted phenyl and heteroaryl; wherein said phenyl is substituted and heteroaryl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F;    F is selected from the group consisting of (C 1-6 )alkyl, (C 3-6 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, (C 1-6 )alkoxy, (C 1-6 )thioalkoxy, cyano, halogen, —C(O)R 57 , benzyl, —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 C(O)—(C 3-6 )cycloalkyl, —NR 42 C(O)-aryl, —NR 42 C(O)-heteroaryl, —NR 42 C(O)-heteroalicyclic, 4, 5, or 6 membered ring cyclic N-lactam, —NR 42 S(O) 2 —(C 1-6 )alkyl, —NR 42 R 43 , C(O)NR 42 R 43  and COOR 54 ; wherein said (C 1-6 )alkyl, (C 3-6 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, (C 1-6 )alkoxy, are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group G;    G is selected from the group consisting of (C 1-6 )alkyl, hydroxy, (C 1-6 )alkoxy, halogen, —NR 48 C(O)—(C 1-6 )alkyl, —NR 48 C(O)—(C 3 )cycloalkyl, 4, 5, or 6 membered ring cyclic N-lactam, —NR 48 S(O) 2 —(C 1-6 )alkyl, NR 48 R 49 , (C 1-6 )alkyl C(O)NR 48 R 49 , C(O)NR 48 R 49  and (C 1-6 )alkylNR 48 R 49 ;    R 40  is hydrogen;    R 41  is (C 1-6 )alkyl, (C 3-7 )cycloalkyl, phenyl, or heteroaryl; wherein said (C 1-6 )alkyl, (C 3-7 )cycloalkyl, phenyl, or heteroaryl are substituted with one to three same or different halogens or one to two same or different methyl, (C 1-3 )alkoxy, heteroaryl or aryl; wherein said aryl or heteroaryl are optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group consisting of (C 1-6 )alkyl, hydroxy, (C 1-6 )alkoxy, —NR 42 C(O)—(C 1-6 )alkyl, NR 42 R 43  and C(O)NR 42 R 43 .    
     
     
         49 . A compound of  claim 2 , including pharmaceutically acceptable salts thereof, wherein: 
 A is selected from the group consisting of phenyl and heteroaryl; wherein heteroaryl is pyridinyl, furanyl or thienyl; and said phenyl or said heteroaryl is optionally substituted with one to two of the same or different amino, C 1-6 alkyl, hydroxy, or halogen;    R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are each independently hydrogen or methyl with the proviso that only one is methyl;    Q is either:                          wherein R 2  is selected from the group consisting of hydrogen, halogen and methoxy; and    R 3  is hydrogen; or    (b) Q is:                          wherein R 2  is halogen or hydrogen; and R 3  is hydrogen;    and for both (a) and (b):    R 4  is selected from the group consisting of B;    B is selected from the group consisting of —C(O)NR 40 R 41 , substituted phenyl, heteroaryl, oxazoline, pyrazinone, methylene dioxy or ethylene dioxy fused to a benzene or pyridine; wherein said heteroaryl or phenyl is optionally substituted with one to three same or different halogens or from one to two same or different substituents selected from the group F;    
     
     
         50 . A compound of  claim 49 , including pharmaceutically acceptable salts thereof, wherein: 
 B is selected from the group consisting of pyrazinone and methylene dioxy or ethylene dioxy fused to a benzene ring; wherein said group is optionally substituted with one to three same or different halogens or a substituent selected from the group F consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NHC(C 1 -C 6  alkyl), —N(C 1 -C 6  alkyl) 2 , -heteroaryl and a 4, 5, or 6 membered cyclic N-lactam.    
     
     
         51 . A compound of  claim 49 , including pharmaceutically acceptable salts thereof, wherein: 
 B is selected from the group consisting of oxadiazole, triazole, pyrazole, pyrazine and pyrimidine; wherein said group is optionally substituted with one to three same or different halogens or a substituent selected from the group F consisting of (C 1 -C 6  alkyl), amino, —NHC(O)—(C 1 -C 6  alkyl), —NHS(O) 2 —(C 1 -C 6  alkyl), methoxy, —C(O)—NH 2 , C(O)NHMe, C(O)NMe2, trifluoromethyl, —NHC(C 1 -C 6  alkyl), —N(C 1 -C 6  alkyl) 2 , -heteroaryl, a 4, 5, or 6 membered cyclic N-lactam and (C 1-6 )alkylNR 48 R 49 .    
     
     
         52 . A compound of  claim 49 , including pharmaceutically acceptable salts thereof, wherein: 
 heteroaryl in B is selected from the group consisting of pyrazine and pyrimidine.    
     
     
         53 . A compound of  claim 50 , including pharmaceutically acceptable salts thereof, wherein: 
 heteroaryl in B is selected from the group consisting of pyrazine and pyrimidine.    
     
     
         54 . A compound of  claim 1  wherein R 9 , R 10 , R 15  and R 16  are each hydrogen; and 
 R 11 , R 12 , R 13 , and R 14  are each independently hydrogen or methyl with the proviso that up to one can be methyl.  
 
     
     
         55 . A compound of  claim 54 , including pharmaceutically acceptable salts thereof, wherein one of R 11 , R 12 , R 13 , and R 14  is methyl.  
     
     
         56 . A compound of  claim 55 , wherein the carbon atom of the piperazine ring to which the methyl group of R 11 , R 12 , R 13 , and R 14  is attached has an (R) configuration.  
     
     
         57 . A compound of  claim 1  wherein R 11 , R 12 , R 13 , and R 14  are each hydrogen; and R 9 , R 10 , R 15  and R 16  are each independently hydrogen or methyl with the proviso that up to one can be methyl.  
     
     
         58 . A compound of  claim 57 , wherein one of R 9 , R 10 , R 15  and R 16  is methyl.  
     
     
         59 . A compound of  claim 58 , wherein the carbon atom of the piperazine ring to which the methyl group of R 9 , R 10 , R 15  and R 16  is attached has an (R) configuration.  
     
     
         60 . A compound of  claim 1 , including pharmaceutically acceptable salts thereof wherein: 
 R 1  is hydrogen;    m is 2;    R 5  is hydrogen;    R 6  does not exist;    A is selected from the group consisting of C 1-6 alkoxy, aryl and heteroaryl; wherein aryl is phenyl; heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl and isoxazolyl; and said aryl or heteroaryl is optionally substituted with one or two of the same or different amino, cyano, hydroxy C 1-6 alkoxy, C 1-6 alkyl, —NHC(O)CH 3 , halogen and trifluoromethyl; and    represents a carbon-carbon bond.    
     
     
         61 . A pharmaceutical formulation which comprises an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, as claimed in  claim 1 , and a pharmaceutically acceptable carrier.  
     
     
         62 . The pharmaceutical formulation of  claim 61 , useful for treating infection by HIV, which additionally comprises an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: 
 (a) an AIDS antiviral agent;    (b) an anti-infective agent;    (c) an immunomodulator; and    (d) HIV entry inhibitors.    
     
     
         63 . A method for treating mammals infected with a virus, comprising administering to said mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, as claimed in  claim 1 .  
     
     
         64 . The method of  claim 63 , comprising administering to said mammal an antiviral effective amount of a compound of Formula I in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and HIV entry inhibitors.  
     
     
         65 . The method of  claim 63  wherein the virus is HIV.  
     
     
         66 . The method of  claim 64  wherein the virus is HIV.  
     
     
         67 . A compound of  claim 1  having the Formula Ia, including pharmaceutically acceptable salts thereof,  
       
         
           
           
               
               
           
         
         wherein:  
         R 2  is methoxy, fluoro or chloro;  
         R 4  is selected from the group consisting of a 1,2,3-triazolyl group having the formula  
         
           
             
             
                 
                 
             
           
         
         a 1,2,4-triazolyl group having the formula  
         
           
             
             
                 
                 
             
           
         
         D is hydrogen or C 1 -C 3  alkyl;  
         E is selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl, O(C 1 -C 3 )alkyl and CH 2 OCH 3 ; and  
         R 11  is either hydrogen or methyl in which the configuration to which the methyl is attached is (R); with the proviso that when R 4  is  
         
           
             
             
                 
                 
             
           
         
         then R 11  is hydrogen.  
       
     
     
         68 . A compound of  claim 67 , including pharmaceutically acceptable salts thereof, wherein: 
 R 2  is methoxy or fluorine;    D is hydrogen or methyl; and    E is hydrogen, methyl or ethyl.    
     
     
         69 . A compound of  claim 68 , including pharmaceutically acceptable salts thereof, wherein: 
 R 2  is methoxy;    D is hydrogen or methyl; and    E is hydrogen, methyl or ethyl.    
     
     
         70 . A compound of  claim 69 , including pharmaceutically acceptable salts thereof, wherein: 
 R 11  is hydrogen.    
     
     
         71 . A compound of  claim 70 , including pharmaceutically acceptable salts thereof, wherein: 
 R 4  is                          and    R 11  is hydrogen.    
     
     
         72 . A compound of  claim 71 , including pharmaceutically acceptable salts thereof, wherein: 
 D is hydrogen.    
     
     
         73 . A compound of  claim 71 , including pharmaceutically acceptable salts thereof, wherein: 
 D is methyl.    
     
     
         74 . A compound of  claim 70 , including pharmaceutically acceptable salts thereof, wherein: 
 R 4  is                          
     
     
         75 . A compound of  claim 74 , including pharmaceutically acceptable salts thereof, wherein: 
 E is hydrogen.    
     
     
         76 . A compound of  claim 74 , including pharmaceutically acceptable salts thereof, wherein: 
 E is methyl.    
     
     
         77 . A compound of  claim 74 , including pharmaceutically acceptable salts thereof, wherein: 
 E is ethyl.    
     
     
         78 . A compound of  claim 68 , including pharmaceutically acceptable salts thereof, wherein: 
 R 2  is fluoro;    D is hydrogen or methyl; and    E is hydrogen or methyl.    
     
     
         79 . A compound of  claim 78 , including pharmaceutically acceptable salts thereof, wherein: 
 R 4  is                          and    R 11  is hydrogen.    
     
     
         80 . A compound of  claim 79 , including pharmaceutically acceptable salts thereof, wherein: 
 D is hydrogen.    
     
     
         81 . A compound of  claim 79 , including pharmaceutically acceptable salts thereof, wherein: 
 D is methyl.    
     
     
         82 . A compound of  claim 78 , including pharmaceutically acceptable salts thereof, wherein: 
 R 4  is                          
     
     
         83 . A compound of  claim 82 , including pharmaceutically acceptable salts thereof, wherein: 
 E is hydrogen.    
     
     
         84 . A compound of  claim 82 , including pharmaceutically acceptable salts thereof, wherein: 
 E is methyl.    
     
     
         85 . A compound of  claim 68 , including pharmaceutically acceptable salts thereof, wherein: 
 R 2  is methoxy;    D is hydrogen or methyl;    E is hydrogen, methyl or ethyl; and    R 11  is (R)-methyl.    
     
     
         86 . A compound of  claim 85 , including pharmaceutically acceptable salts thereof, wherein: 
 R 4  is                          
     
     
         87 . A compound of  claim 86 , including pharmaceutically acceptable salts thereof, wherein: 
 E is hydrogen.    
     
     
         88 . A compound of  claim 86 , including pharmaceutically acceptable salts thereof, wherein: 
 E is methyl.    
     
     
         89 . A compound of  claim 86 , including pharmaceutically acceptable salts thereof, wherein: 
 E is ethyl.    
     
     
         90 . A pharmaceutical formulation which comprises an antiviral effective amount of a compound of Formula Ia, including pharmaceutically acceptable salts thereof, as claimed in  claim 67 , and a pharmaceutically acceptable carrier.  
     
     
         91 . The pharmaceutical formulation of  claim 90 , useful for treating infection by HIV, which additionally comprises an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: 
 (a) an AIDS antiviral agent;    (b) an anti-infective agent;    (c) an immunomodulator; and    (d) HIV entry inhibitors.    
     
     
         92 . A method for treating mammals infected with the HIV virus, comprising administering to said mammal an antiviral effective amount of a compound of Formula Ia, including pharmaceutically acceptable salts thereof, as claimed in  claim 67 .  
     
     
         93 . The method of  claim 92 , comprising administering to said mammal an antiviral effective amount of a compound of Formula Ia in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and HIV entry inhibitors.